ASCT	autologous stem cell transplantation
BM	bone marrow
BM-MSC	bone marrow-derived mesenchymal stem cells
CR	complete response
CRAB	calcium-elevated, renal failure, anemia, and bone lesions
CXCL1	C-X-C motif chemokine ligand
GM-CSF	granulocyte, monocyte colony-stimulating factor
IFN	interferon
IL-1-Ra	IL-1 receptor antagonist
IMiDs	immunomodulatory drugs
IMWG	International Myeloma Working Group
LCD	light chain disease
LDH	lactate dehydrogenase
MIP	macrophage inflammatory protein
MM	multiple myeloma
MSC	mesenchymal stem cells
OS	overall survival
PC	plasma cells
PCM	plasma cell myeloma
PD	progressive disease
PDGF	platelet-derived growth factor
PFS	progression-free survival
PI	proteasome inhibitor
POEMS	polyradiculoneuropathy, organomegaly, endocrinopathy, M-spike, skin changes
PR	partial resposne
RANTES	regulated upon activation, normal T cell expressed, and presumably secreted
SD	stable disease
TGF-β	transforming growth factor β
TNF	tumor necrosis factor
VCD	bortezomib, cyclophosphamide, dexamethasone
VEGF	vascular endothelial growth factor
VGPR	very good partial response
VMP	bortezomib, melphalan, and prednisone
VTD	bortezomib, thalidomide, dexamethasone